Clinical Trials Sponsored by Plasma Services Group

Total 452 results

The Plasma Source
Plasma Services Group

Unknown

300 Antibody Diagnostic Test Kit (Antibody 300)

Acute Bacterial Infections | Acute Viral Infections

United States
Eisai Inc.
PPD; MDS Pharma Services; Bio Analytical Research Corporation; Coghlan Group (Plasma...

Completed

A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Elective Colonoscopy

Colonoscopy | Colon Polyps
Ascentage Pharma Group Inc.
Tanner Pharma Group

Available

Named Patient Program for Olverembatinib (HQP1351)
Celtic Pharma Development Services

Terminated

Tolerability Study of Xerecept® in Pediatric Patients

Brain Tumor | Brain Edema

United States
Celtic Pharma Development Services

Completed

Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation

Smoking

United States
Celtic Pharma Development Services

Completed

Xerecept Intravenous Dose Escalation in Japanese and Caucasian Volunteers

Edema

United States
Chugai Pharma France
ITEC Services

Completed

Assessment of Giant Cell Arteritis Medical Practices in France (ARTEMIS)

Giant Cell Arteritis

France
Celtic Pharma Development Services
PPD

Unknown

TDT 067 Onychomycosis Study

Onychomycosis

United States
Queen's University
Pfizer; Providence Health & Services; MDS Pharma Services

Completed

An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression

Depression, Bipolar

Canada
VIVUS LLC
MDS Pharma Services

Completed

A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.

Obesity | Overweight

United States
Celtic Pharma Development Services
PPD

Completed

TDT 067 Open Label Multi-Dose Onychomycosis Study

Onychomycosis
PharmaNet
Celtic Pharma Development Services

Terminated

Imaging Study of XERECEPT® Treatment for Peritumoral Brain Edema (PBE)

Peritumoral Brain Edema | PRIMARY MALIGNANT and METASTATIC BRAIN TUMORS
Providence Health & Services
Prometheus Laboratories; Cytokine Working Group

Active, not recruiting

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

Renal Cell Carcinoma

United States
Inova Health Care Services
Mednax National Medical Group

Completed

Pain Management in Response to Exparel vs. Standard Bupivicaine (VATS Exparel)

Pain

United States
Luye Pharma Group Ltd.

Recruiting

Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects

Tardive Dyskinesia | Huntington Disease

China
Luye Pharma Group Ltd.

Not yet recruiting

Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg

Prostate Cancer

China
Luye Pharma Group Ltd.

Recruiting

Comparative Efficacy, Safety, PK, and Immunogenicity Study of LY06006 and EU-Prolia in Postmenopausal Women With Osteoporosis

Osteoporosis, Postmenopausal

China
Advice Pharma Group srl

Recruiting

KidneYou - Innovative Digital Therapy

Diabetes | Chronic Kidney Diseases | Tuberous Sclerosis | Albuminuria | Treatment Adherence | Arterial Hypertension | Treatment Adherence and Compliance | Nephronophthisis | Polycystic Kidney | Chronic Glomerulonephritis | Cystic Kidney Diseases | Cortical Cystic Disease | Cystic Diseases

Italy
Ascentage Pharma Group Inc.

Recruiting

APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

NHL, Adult

China
Ascentage Pharma Group Inc.

Recruiting

A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors

Neuroendocrine Tumors

China
Ascentage Pharma Group Inc.

Recruiting

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With T-PLL

T-Prolymphocytic Leukemia

United States
Ascentage Pharma Group Inc.

Recruiting

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China
Ascentage Pharma Group Inc.

Recruiting

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | AML | MDS | CMML | High-risk Myelodysplastic Syndrome

United States
Ascentage Pharma Group Inc.

Recruiting

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Myeloid Leukemia | Chronic Myeloid Leukemia | Philadelphia Positive Acute Lymphoblastic Leukemia | Leukemia, Myeloid, Chronic | B Cell Precursor Type Acute Leukemia

United States
Ascentage Pharma Group Inc.

Recruiting

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

Hematologic Malignancies

United States, Australia
Advice Pharma Group srl

Active, not recruiting

DEMETRA - ADVICE-002-2022

Obesity | Nutrition Disorders | Body Weight | Weight Loss | Dietary Habits | Overweight and Obesity | Health Behavior | Diet, Healthy | Diet Habit | Life Style | Nutrition, Healthy | Behavioral Disorder

Italy
Luye Pharma Group Ltd.

Completed

A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects

Tardive Dyskinesia | Huntington Disease

China
Ascentage Pharma Group Inc.

Completed

The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy Subjects

Pharmacokinetics

China
Luye Pharma Group Ltd.

Completed

Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer

Advanced Breast Cancer

China
Luye Pharma Group Ltd.

Completed

A Dose-escalation Study of LPM3480392 in Chinese Healthy Subjects

Healthy

China
Luye Pharma Group Ltd.

Completed

Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Prostate Cancer

China
Luye Pharma Group Ltd.

Completed

An Exploratory Study of LPM3480392 at Different Infusion Rates in Chinese Healthy Subjects

Healthy

China
Luye Pharma Group Ltd.

Active, not recruiting

Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer

Small Cell Lung Cancer

China
Ascentage Pharma Group Inc.

Active, not recruiting

A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation

Chronic Myeloid Leukemia, Chronic Phase

China
Ascentage Pharma Group Inc.

Active, not recruiting

A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation

Chronic Myeloid Leukemia - Accelerated Phase

China
Ascentage Pharma Group Inc.

Withdrawn

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Myelofibrosis

United States
Ascentage Pharma Group Inc.

Completed

A Study of APG-1252 in Patients With SCLC or Other Solid Tumors

Small Cell Lung Cancer | Solid Tumor

United States
ACTEON Group
Slb Pharma

Completed

Efficacy of a Collagen Hemostatic Dressing After Tooth Extraction

Tooth Avulsion

France
Luye Pharma Group Ltd.

Enrolling by invitation

to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers

Parkinson's Disease

Australia
Luye Pharma Group Ltd.

Completed

A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro

Parkinson Disease

United States
Mesoestetic Pharma Group S.L.

Completed

Evaluation of the Efficacy and Safety of the Dermal Filler for Female Intimate Area Hydration and Atrophy of the Vagina.

Urinary Incontinence | Vaginal Atrophy | Vulvovaginal Signs and Symptoms | Dyspareunia

Bulgaria
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003

Parkinson Disease
ACTEON Group
Slb Pharma

Completed

Pain After Root Canal Obturation With Sealer Containing or Not 1% Enoxolone

Root Canal Obturation

France
Luye Pharma Group Ltd.

Completed

A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

Schizophrenia | Schizoaffective Disorder | Schizo Affective Disorder

United States
Luye Pharma Group Ltd.

Completed

Pilot BA Study of New LY03005 vs Pristiq

Major Depression

United States
Luye Pharma Group Ltd.

Completed

Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

Parkinson's Disease

United States
Luye Pharma Group Ltd.

Completed

Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005

Major Depressive Disorder, Recurrent, Unspecified

United States
Luye Pharma Group Ltd.

Completed

Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease (03003MAD)

Parkinson's Disease

United States
Luye Pharma Group Ltd.

Completed

An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder

United States
Luye Pharma Group Ltd.

Completed

Bioavailability of LY03004 and Risperdal® Consta®

Schizophrenia | Schizoaffective Disorder

United States

Clinical Trials Sponsored by Plasma Services Group

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations